FF-10832
As of the edition of 20 October 2026, FF-10832 is a drug known only by a code name: in active development; acts on POLA1, POLA2 and POLD1 and 11 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2029
- Kind
- Code name only
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| POLA1 | DNA polymerase alpha catalytic subunit | P09884 |
| RRM1 | Ribonucleoside-diphosphate reductase large subunit | P23921 |
| POLD1 | DNA polymerase delta catalytic subunit | P28340 |
| RRM2 | Ribonucleoside-diphosphate reductase subunit M2 | P31350 |
| POLD2 | DNA polymerase delta subunit 2 | P49005 |
| PRIM1 | DNA primase small subunit | P49642 |
| PRIM2 | DNA primase large subunit | P49643 |
| POLE2 | DNA polymerase epsilon subunit 2 | P56282 |
| POLE | DNA polymerase epsilon catalytic subunit A | Q07864 |
| POLA2 | DNA polymerase alpha subunit B | Q14181 |
| POLD3 | DNA polymerase delta subunit 3 | Q15054 |
| RRM2B | Ribonucleoside-diphosphate reductase subunit M2 B | Q7LG56 |
| POLD4 | DNA polymerase delta subunit 4 | Q9HCU8 |
| POLE3 | DNA polymerase epsilon subunit 3 | Q9NRF9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Fujifilm Pharmaceuticals | Lead sponsor of trials | 2022 to now |